One platform connecting startups, corporations, research institutions, regions and investors
Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
EDTECH: LEVERAGING AI-POWERED TECHNOLOGIES TO TRANSFORM THE LEARNING EXPERIENCE
1. Technology overview
Skin Analytics is a company that its own news release calls a British healthtech business, built around the mission that nobody dies of skin cancer. It develops DERM, an AI medical device for skin cancer detection that the site says has been in live use for over six years.
DERM works with a dermascope in clinics, and DERM Zero runs on a standard smartphone. It is CE-marked Class III under EU MDR and used across more than 40 NHS partners, as well as private insurance pathways with partners such as Bupa and Vitality. In the United States it is described as an investigational device.
2. Highlighted features & specifications
- DERM: Class III CE-marked AI that assesses skin lesions imaged with a dermascope.
- DERM Zero: Smartphone version that needs no dermascope.
- Autonomous pathway: Supports discharge of low-risk lesions without a specialist visit.
- Care pathway support: Works across primary care, secondary care and private insurance.
- Teledermatology expansion: Funding is directed at broader dermatology products and tele-infrastructure.
3. Potential application
Private dermatology clinics in Vietnam can pre-screen pigmented lesions. Health insurers can pilot teledermatology skin checks. Occupational health programs can run skin screening for outdoor workers.
4. Benefits
Autonomous assessment can discharge low-risk lesions without a face-to-face dermatology visit.
Deployed at 26 NHS sites by April 2025, with pathways covering 150,000+ patients and 14,000+ cancers detected (company figures).
Smartphone-based DERM Zero removes the need for a dermascope.
Supports primary care, secondary care and insurance pathways.
5. Market trends & opportunities
Skin cancer referral volumes strain dermatology services, and autonomous AI triage is moving from pilots to routine care in Europe. In Vietnam, dermatologists are concentrated in large cities, so smartphone-based triage could widen access.
6. Other information
Raised GBP 15M Series B in April 2025, led by Intrepid Growth Partners, after DERM's EU MDR Class III CE mark. Over 40 NHS partners; footer copyright range 2012-2026. TIME HealthTech 2026 award link on the homepage.
